First Trust Advisors LP Allogene Therapeutics, Inc. Transaction History

First Trust Advisors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $253,820 - $425,001	24,595 New	24,595 $266,000
Q2 2019 Jul 30, 2019	SELL	$25.56 - $31.09 $2.6 Million - $3.17 Million	-101,816 Closed	0 $0
Q1 2019 May 09, 2019	BUY	$24.82 - $32.54 $9,307 - $12,202	375 Added 0.37%	101,816 $2.94 Million
Q4 2018 Feb 07, 2019	BUY	$22.5 - $33.3 $2.28 Million - $3.38 Million	101,441 New	101,441 $2.73 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.